HOME

Anchor 1

Transforming Diabetic Foot Ulcer Care in Saudi Arabia

A Saudi healthcare company delivering SFDA‑approved, AI‑enabled biotherapeutic solutions for chronic foot ulcers, with the ambition to make the Kingdom a regional centre of excellence.

Diabetic foot ulcers are one of the most serious and costly complications of diabetes in Saudi Arabia, driving thousands of amputations and placing a heavy burden on patients, families, and hospitals. Madarik introduces an innovative autologous biotherapeutic treatment designed to improve healing rates, reduce amputations, and lower the long‑term cost of care for the Kingdom’s health system.

“Why it matters”

In Saudi Arabia, more than 4.2 million adults live with diabetes and around 12% will develop a diabetic foot ulcer during their lifetime, contributing to over 3,000 amputations a year. Our mission is to change this trajectory by combining advanced biotherapeutic science, rigorous clinical evidence, and AI‑enabled tools tailored to the needs of patients and clinicians in the Kingdom

SFDA‑approved biotherapeutic treatment for diabetic foot ulcers.
Backed by FDA‑licensed trials, ISO‑certified quality, and real‑world evidence
Developed in Saudi Arabia to support Vision 2030 and increase local healthcare content.